Heathre Moler Appointed Danaher Chief HR Officer
Danaher is set for change at the top of its executive leadership team, with Heathre Moler set to take on the role of Chief HR Officer from 1 October 2026.
She will replace Georgeann Couchara, who has held the position since April 2022.
Danaher is a global science and technology company focused on biotechnology, diagnostics and life sciences. Its portfolio includes businesses such as Cytiva, Beckman Coulter, Cepheid and Leica Biosystems, providing tools, technologies and services spanning drug development, biomanufacturing and precision diagnostics.
Danaher generated around US$25bn in revenue in 2025.
Commenting on the appointment, incoming CEO and President of Danaher, Julie Sawyer Montgomery, says, “Heathre is an enterprise-minded leader who understands how talent, culture, leadership and the Danaher Business System connect directly to business performance, and she has earned the trust of teams across multiple Danaher businesses, most recently Diagnostics.
“I'm confident she will be a strong partner as we continue strengthening the leadership bench, organisational capability and culture Danaher needs for our next chapter.”
- US$24.6bn revenue generated by Danaher in 2025, with Diagnostics its largest segment at US$9.9bn.
- More than 60,000 associates across more than 15 operating companies and approximately 50 countries.
- Three core divisions: Biotechnology, Life Sciences and Diagnostics.
- Danaher Business System (DBS) underpins the company's operating model, combining continuous improvement with a focus on growth, lean operations and leadership.
Hiring from within
Heathre enters the top HR role at Danaher, having spent more than a decade at the firm.
Joining in 2013, she has held HR leadership roles across Danaher’s Water Quality Platform, Hach, ChemTreat and Thomson Industries divisions.
Previously, she spent more than a decade at ETS-Lindgren, a supplier of energy management solutions for the industrial and commercial markets.
Discussing her new role on LinkedIn, Heather writes, “I am honoured to step into this role as CHRO [at] Danaher and grateful for the trust placed in me to help shape our people, culture and leadership in the years ahead.
“Thank you to Georgeann Couchara for the strong foundation she leaves behind, and to the many leaders and teams across Danaher who have shaped my journey along the way.”
âI am honored to step into this role as CHRO [at] Danaher and grateful for the trust placed in me to help shape our people, culture and leadership in the years ahead. â
Executive change at Danaher
Heathre’s appointment follows Danaher’s announcement on 3 August 2026 that Julie Sawyer Montgomery will take on the role of CEO and President from 1 October 2026 – the same date that Heathre’s tenure as Chief HR Officer begins.
Rainer Blair, who has served as Danaher CEO since 2020, will soon retire from the role but will support the transition as a senior advisor until 31 March 2027.
Julie brings nearly 25 years of healthcare, commercial and R&D experience to the role. She joined Danaher in 2017 at Beckman Coulter Diagnostics, becoming President in 2020 after leading commercial operations and R&D.
She has since held increasingly senior roles, most recently serving as Danaher Executive Vice President and leading its Diagnostics business from 2023. Under her leadership, Diagnostics nearly doubled revenue from around US$6 billion to US$11 billion, while operating profit roughly tripled.
A busy period for Danaher
The appointments of Heathre and Julie come as Danaher prepares for its next phase of growth.
The company is coming off a US$24.6bn revenue year in 2025, with Biotechnology, Life Sciences and Diagnostics generating US$7.3bn, US$7.3bn and US$9.9bn respectively.
Acquisitions have also been central to Danaher’s growth strategy, with a significant proportion of its current revenue coming from businesses acquired over the past decade.
Recent deals include the US$9.9bn acquisition of Masimo, completed in June 2026, strengthening its Diagnostics portfolio with patient-monitoring and pulse-oximetry technologies.
Earlier major acquisitions include Abcam, Aldevron and Cytiva, expanding Danaher’s capabilities across life sciences, genomics and biopharmaceutical manufacturing.
The company is also pursuing the acquisition of StatLab, adding further pathology capabilities to Leica Biosystems.
Key Danaher Partners
CEO: Joe Kiani | HQ: Irvine, California
Masimo develops non-invasive patient monitoring technologies, including pulse oximetry, sensors and connectivity platforms. Danaher completed its US$9.9bn acquisition in June 2026, making Masimo a wholly owned subsidiary within its Diagnostics segment while retaining the Masimo brand and standalone operating structure.
CEO: Pascal Soriot | HQ: Cambridge, UK
AstraZeneca is a global biopharmaceutical company focused on oncology, rare diseases and biopharmaceuticals. In 2025, it partnered with Danaher to develop and commercialise novel diagnostics for precision medicine, initially focusing on digital and computational pathology and AI-assisted algorithms through Danaher’s Leica Biosystems. The collaboration aims to improve identification of patients most likely to benefit from targeted therapies.
CEO: Abhinav Shashank | HQ: San Francisco, California
Innovaccer is a healthcare AI and data company providing platforms designed to connect healthcare data and support clinical decision-making. Danaher announced an investment partnership with Innovaccer in January 2025, combining Danaher’s diagnostics expertise with Innovaccer’s data and AI capabilities to advance diagnostic and clinical AI solutions.
Company portals
Executives
Heathre Moler
Chief Human Resources Officer (CHRO) Designate
Julie Sawyer Montgomery
President
